Survival and prognostic factors in hepatitis B virus-related acute-on-chronic liver failure

Table 1 Complications and laboratory tests in patients with hepatitis B virus-related acute-on-chronic liver failure (mean ± SD) n (%)

Complications and biochemical characteristics	Entecavir group	Lamivudine group	Non-antiviral group
No. of patients	77	64	49
Gender (M/F)	66/11	56/8	37/12
Age (yr)	45.90 ± 11.33	44.38 ± 10.39	47.20 ± 11
Ascites	64 (83.1)	53 (82.8)	35 (71.4)
HRS	7 (9.1)	6 (9.4)	3 (6.1)
HE	23 (29.9)	22 (34.4)	19 (38.8)
I-II	19 (24.7)	18 (28.1)	16 (32.7)
III-IV	4 (5.2)	4 (6.3)	3 (6.1)
SBP	23 (29.9)	21 (32.8)	19 (38.8)
Liver cirrhosis	48 (62.3)	38 (59.4)	34 (69.4)
Electrolyte disturbances	54 (70.1)	49 (76.6)	41 (83.7)
Alanine transaminase (U/L)	412.84 ± 605.62	271.14 ± 304.24	180.96 ± 222.50
Total bilirubin (μmol/L)	311.34 ± 120.99	340.81 ± 123.38	265.51 ± 121.88
Albumin (g/L)	37.25 ± 11.84	34.09 ± 10.90	35.76 ± 12.34
Prothrombin activity (%)	32.16 ± 9.21	31.36 ± 10.16	31.64 ± 10.59
International normalized ratio	2.46 ± 0.69	2.47 ± 0.61	2.58 ± 0.86
Creatinine (μmol/L)	97.78 ± 55.42	88.85 ± 25.08	96.94 ± 38.16
Sodium (mmol/L)	133.57 ± 13.37	133.52 ± 6.47	132.57 ± 5.61
HBeAg (+/-)	33/44	27/37	22/27
HBV DNA (IU/mL)	(1.00 ± 8.51) × 108	(4.00 ± 26.69) × 107	(4.41 ± 1.08) × 107
HBV DNA level (< 103/103-107/> 107)	4/61/11	3/52/10	4/39/6
MELD score	29.07 ± 4.02	28.69 ± 4.43	28.61 ± 3.49
MELD score (< 30/≥ 30)	47/30	41/23	34/15

HRS: Hepatorenal syndrome; HE: Hepatic encephalopathy; SBP: Spontaneous bacterial peritonitis; HBV: Hepatitis B virus; MELD: Model for end-stage liver disease.